The findings support extended anticoagulation in patients with active, ongoing cancer and isolated distal DVT, with caveats, including the need for individualized patient treatment decisions.
Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), according to late breaking research.